SIRT1 prevents pulmonary thrombus formation induced by arachidonic acid via downregulation of PAF receptor expression in platelets

References

• Kearon C, Akl EA. Duration of anticoagulant therapy for deep vein thrombosis and pulmonary embolism. Blood 2014;123:1794–1801.
   PubMed Web of Science ®Google Scholar
• Chung T, Connor D, Joseph J, Emmett L, Mansberg R, Peters M, Ma D, Kritharides L. Platelet activation in acute pulmonary embolism. J Thromb Haemost 2007;5:918–924.
   PubMed Web of Science ®Google Scholar
• Kearon C, Akl EA, Comerota AJ, Prandoni P, Bounameaux H, Goldhaber SZ, Nelson ME, Wells PS, Gould MK, Dentali F, et al. Antithrombotic therapy for VTE disease: Antithrombotic therapy and prevention of thrombosis, 9th ed. American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012;141(2Suppl): e419S–94S.
   Google Scholar
• Pulmonary Embolism Prevention (PEP) Trial Collaborative Group. Prevention of pulmonary embolism and deep vein thrombosis with low dose aspirin: Pulmonary Embolism Prevention (PEP) trial. Lancet 2000;355:1295–1302.
   Google Scholar
• da Costa Martins PA, van Gils JM, Mol A, Hordijk PL, Zwaginga JJ. Platelet binding to monocytes increases the adhesive properties of monocytes by up-regulating the expression and functionality of beta1 and beta2 integrins. J Leukoc Biol 2006;79:499–507.
   PubMed Web of Science ®Google Scholar
• Offermanns S. Activation of platelet function through G protein-coupled receptors. Circ Res 2006;99:1293–1304.
   PubMed Web of Science ®Google Scholar
• Millard M, Odde S, Neamati N. Integrin targeted therapeutics. Theranostics 2011;1:154–188.
   PubMed Web of Science ®Google Scholar
• Parise LV, Venton DL, Le Breton GC. Arachidonic acid-induced platelet aggregation is mediated by a thromboxane A2/prostaglandin H2 receptor interaction. J Pharmacol Exp Ther 1984;228:240–244.
   PubMed Web of Science ®Google Scholar
• Agarwal KC, Clarke E, Rounds S, Parks RE Jr, Huzoor-Akbar. Platelet-activating factor (PAF)-induced platelet aggregation. Modulation by plasma adenosine and methylxanthines. Biochem Pharmacol 1994;48:1909–1916.
   Google Scholar
• Kim YH, Lee SJ, Seo KW, Bae JU, Park SY, Kim EK, Bae SS, Kim JH, Kim CD. PAF enhances MMP-2 production in rat aortic VSMCs via a β-arrestin2-dependent ERK signaling pathway. J Lipid Res 2013;54:2678–2686.
   PubMed Web of Science ®Google Scholar
• Watkins SM, Hotamisligil GS. Promoting atherosclerosis in type 1 diabetes through the selective activation of arachidonic acid and PGE (2) production. Circ Res 2012;111:394–396.
   PubMed Web of Science ®Google Scholar
• Lavu S, Boss O, Elliott PJ, Lambert PD. Sirtuins-novel therapeutic targets to treat age-associated diseases. Nat Rev Drug Discov 2008;7:841–853.
   PubMed Web of Science ®Google Scholar
• Han L, Zhou R, Niu J, McNutt MA, Wang P, Tong T. SIRT1 is regulated by a PPAR {γ}-SIRT1 negative feedback loop associated with senescence. Nucleic Acids Res 2010;38:7458–7471.
   PubMed Web of Science ®Google Scholar
• Zhang QJ, Wang Z, Chen HZ, Zhou S, Zheng W, Liu G, Wei YS, Cai H, Liu DP, Liang CC. Endothelium-specific overexpression of class III deacetylase SIRT1 decreases atherosclerosis in apolipoprotein E-deficient mice. Cardiovasc Res 2008;80:191–199.
   PubMed Web of Science ®Google Scholar
• Milne JC, Lambert PD, Schenk S, Carney DP, Smith JJ, Gagne DJ, Jin L, Boss O, Perni RB, Vu CB, et al. Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes. Nature 2007;450:712–716.
   PubMed Web of Science ®Google Scholar
• Banks AS, Kon N, Knight C, Matsumoto M, Gutiérrez-Juárez R, Rossetti L, Gu W, Accili D. SirT1 gain of function increases energy efficiency and prevents diabetes in mice. Cell Metab 2008;8:333–341.
   PubMed Web of Science ®Google Scholar
• Lee JH, Song MY, Song EK, Kim EK, Moon WS, Han MK, Park JW, Kwon KB, Park BH. Overexpression of SIRT1 protects pancreatic beta-cells against cytokine toxicity by suppressing the nuclear factor-kappaB signaling pathway. Diabetes 2009;58:344–351.
   PubMed Web of Science ®Google Scholar
• Breitenstein A, Stein S, Holy EW, Camici GG, Lohmann C, Akhmedov A, Spescha R, Elliott PJ, Westphal CH, Matter CM, et al. Sirt1 inhibition promotes in vivo arterial thrombosis and tissue factor expression in stimulated cells. Cardiovasc Res 2011;89:464–472.
   PubMed Web of Science ®Google Scholar
• Wu Z, Liu MC, Liang M, Fu J. Sirt1 protects against thrombomodulin down-regulation and lung coagulation after particulate matter exposure. Blood 2012;119:2422–2429.
   PubMed Web of Science ®Google Scholar
• Kim YH, Bae JU, Lee SJ, Park SY, Kim CD. SIRT1 attenuates PAF-induced MMP-2 production via down-regulation of PAF receptor expression in vascular smooth muscle cells. Vascul Pharmacol 2015;72:35–42.
   PubMed Web of Science ®Google Scholar
• Gagnon AW, Kallal L, Benovic JL. Role of clathrin-mediated endocytosis in agonist-induced down-regulation of the beta2-adrenergic receptor. J Biol Chem 1998;273:6976–6981.
   PubMed Web of Science ®Google Scholar
• Law PY, Hom DS, Loh HH. Down-regulation of opiate receptor in neuroblastoma x glioma NG108-15 hybrid cells. Chloroquine promotes accumulation of tritiated enkephalin in the lysosomes. J Biol Chem 1984;259:4096–4104.
   Google Scholar
• Dupré DJ, Chen Z, Le Gouill C, Thériault C, Parent JL, Rola-Pleszczynski M, Stankova J. Trafficking, ubiquitination, and down-regulation of the human platelet-activating factor receptor. J Biol Chem 2003;278:48228–482235.
   PubMed Web of Science ®Google Scholar
• Parente L. pros and cons of selective inhibition of cyclooxygenase-2 versus dual lipoxygenase/cyclooxygenase inhibition: is two better than one? J Rheumatol 2001;28:2375–2382.
   PubMed Web of Science ®Google Scholar
• Schafer AI, Adelman B. Plasmin inhibition of platelet function and of arachidonic acid metabolism. J Clin Invest 1985;75:456–461.
   PubMed Web of Science ®Google Scholar
• Yano T, Fujioka D, Saito Y, Kobayashi T, Nakamura T, Obata JE, Kawabata K, Watanabe K, Watanabe Y, Mishina H, et al. Group V secretory phospholipase A2 plays a pathogenic role in myocardial ischaemia-reperfusion injury. Cardiovasc Res 2011;90:335–343.
   PubMed Web of Science ®Google Scholar
• Saito Y, Watanabe K, Fujioka D, Nakamura T, Obata JE, Kawabata K, Watanabe Y, Mishina H, Tamaru S, Kita Y, et al. Disruption of group IVA cytosolic phospholipase A(2) attenuates myocardial ischemia-reperfusion injury partly through inhibition of TNF-α-mediated pathway. Am J Physiol Heart Circ Physiol 2012;302:H2018–H2030.
   PubMed Web of Science ®Google Scholar
• Takahashi S, Suzuki K, Watanabe Y, Watanabe K, Fujioka D, Nakamura T, Obata JE, Kawabata K, Mishina H, Kugiyama K. Phospholipase A2 expression in coronary thrombus is increased in patients with recurrent cardiac events after acute myocardial infarction. Int J Cardiol 2013;168:4214–4221.
   PubMed Web of Science ®Google Scholar
• Kumar Vinay, Abbas Abul K, Aster Jon C, Fausto Nelson. Robbins & Cotran Pathologic Basis of Disease, 8th ed. St. Louis: Saunders/Elsevier; 2010.
   Google Scholar
• Morita A, Mori M, Hasegawa K, Kojima K, Kobayashi S. Anti-platelet aggregating and disaggregating activities of 6,9-methano PGI2. Life Sci 1980;27:695–701.
   PubMed Web of Science ®Google Scholar
• Kihara Y, Mizuno H, Chun J. Lysophospholipid receptors in drug discovery. Exp Cell Res 2015;333:171–177.
   PubMed Web of Science ®Google Scholar
• Hara T, Kimura I, Inoue D, Ichimura A, Hirasawa A. Free fatty acid receptors and their role in regulation of energy metabolism. Rev Physiol Biochem Pharmacol 2013;164:77–116.
   PubMed Web of Science ®Google Scholar